Compass Files Psilocybin Application with FDA as U.S. Government Supports Ibogaine Development and the Field Assesses Midterms
Summary
Compass Pathways has submitted a psilocybin new drug application to the FDA, while the U.S. government has tapped Mark Cuban's company to support ibogaine development for PTSD. The government has also committed to funding a $20 million real-world evidence network. Josh Hardman reviews these developments alongside the potential implications of the U.S. midterms for psychedelics and Delix Therapeutics' $100 million Series C raise. The episode surveys news from the preceding two weeks but supplies few details about the individual developments.